CEFAZOLIN FOR INJECTION POWDER FOR SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

CEFAZOLIN (CEFAZOLIN SODIUM)

Saadav alates:

TEVA CANADA LIMITED

ATC kood:

J01DB04

INN (Rahvusvaheline Nimetus):

CEFAZOLIN

Annus:

1G

Ravimvorm:

POWDER FOR SOLUTION

Koostis:

CEFAZOLIN (CEFAZOLIN SODIUM) 1G

Manustamisviis:

INTRAMUSCULAR

Ühikuid pakis:

10

Retsepti tüüp:

Prescription

Terapeutiline ala:

FIRST GENERATION CEPHALOSPORINS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0109442001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2013-04-11

Toote omadused

_Pr_
_CEFAZOLIN FOR INJECTION Product Monograph Page 1 of 21 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CEFAZOLIN FOR INJECTION
POWDER FOR SOLUTION, 500 MG, 1.0 G AND 10.0 G, CEFAZOLIN (AS CEFAZOLIN
SODIUM) PER VIAL
Intravenous, Intramuscular
USP
Antibiotic
Teva Canada Limited
Date of Initial Authorization:
30 Novopharm Court
January 19, 1995
Toronto, Ontario
M1B 2K9
Date of Revision:
Canada
MAR 15, 2024
www.tevacanada.com
Submission Control Number: 265641
_Pr_
_CEFAZOLIN FOR INJECTION (Cefazolin Sodium) Product Monograph Page 2
of 21 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
11/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
1 INDICATIONS
..........................................................................................................................
3
2 CONTRAINDICATIONS
.........................................................................................................
4
4
DOSAGE AND ADMINISTRATION
......................................................................................
4
4.2 Recommended Dose and Dosage Adjustment
......................................................................
4
4.3 Reconstitution
.......................................................................................................................
6
4.4 Administration
......................................................................................................................
8
5 OVERDOSAGE
.........................................................................................................................
8
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKA